Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Ranolazine Roche Bioscience.

R Jones1

  • 1Selly Oak Hospital, Department of Clinical Biochemistry, Birmingham University NHS Trust, Birmingham, B29 6JD, UK.

Idrugs : the Investigational Drugs Journal
|October 4, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Ultrastructural analysis of contractile cell development in lung microvessels in hyperoxic pulmonary hypertension. Fibroblasts and intermediate cells selectively reorganize nonmuscular segments.

The American journal of pathology·1992
Same author

ACP Broadsheet No 134: December 1992. How to harvest bone marrow for transplantation.

Journal of clinical pathology·1992
Same author

Identification of an abundant monkey epididymal transcript encoding a homologue of human CAMPATH-1 antigen precursor.

Biochimica et biophysica acta·1992
Same author

Eating habits and eating disorders during pregnancy.

Psychosomatic medicine·1992
Same author

Effect of radiation dose on the development of mixed haemopoietic chimerism following T cell-depleted allogeneic bone marrow transplantation.

Bone marrow transplantation·1992
Same author

Reasons for consultation in irritable bowel syndrome: symptoms and patient characteristics.

The British journal of general practice : the journal of the Royal College of General Practitioners·1992
Same journal

Filibuvir, a non-nucleoside NS5B polymerase inhibitor for the potential oral treatment of chronic HCV infection.

IDrugs : the investigational drugs journal·2010
Same journal

Remimazolam, a short-acting GABA(A) receptor agonist for intravenous sedation and/or anesthesia in day-case surgical and non-surgical procedures.

IDrugs : the investigational drugs journal·2010
Same journal

LX-1031, a tryptophan 5-hydroxylase inhibitor that reduces 5-HT levels for the potential treatment of irritable bowel syndrome.

IDrugs : the investigational drugs journal·2010
Same journal

Dexpramipexole, the R(+) enantiomer of pramipexole, for the potential treatment of amyotrophic lateral sclerosis.

IDrugs : the investigational drugs journal·2010
Same journal

Lu-AA21004, a multimodal serotonergic agent, for the potential treatment of depression and anxiety.

IDrugs : the investigational drugs journal·2010
Same journal

Florbetapir (18F), a PET imaging agent that binds to amyloid plaques for the potential detection of Alzheimer's disease.

IDrugs : the investigational drugs journal·2010
See all related articles

Ranolazine, a metabolic modulator, shows promise for treating angina and intermittent claudication by improving muscle cell energy output. Clinical trials indicate it enhances exercise tolerance in patients with ischemic heart disease.

Area of Science:

  • Cardiology
  • Metabolic Medicine
  • Pharmacology

Background:

  • Ranolazine is a novel metabolic modulator targeting energy metabolism in cardiac and muscle cells.
  • It is developed for treating angina and peripheral arterial disease, particularly intermittent claudication.
  • Existing therapies for these conditions are often ineffective for a significant patient population.

Purpose of the Study:

  • To evaluate the efficacy of ranolazine as an anti-anginal agent.
  • To assess ranolazine's effectiveness in treating peripheral arterial disease, specifically intermittent claudication.
  • To determine ranolazine's safety and tolerability in patients with ischemic heart disease.

Main Methods:

  • Phase III clinical trials involving placebo-controlled, double-blind, and multicenter studies.

Related Experiment Videos

  • Enrollment of angina patients and patients with ischemic heart disease.
  • Evaluation of exercise tolerance and cardiac function parameters.

    • Main Results:

    • Ranolazine demonstrated increased exercise times to the onset of angina in Phase II trials.
    • It functions by enhancing carbohydrate utilization as fuel, potentially via pyruvate dehydrogenase activation and L-type calcium channel modulation.
    • The drug appears to maintain muscle cell energy output under hypoxic conditions without negatively impacting heart rate or blood pressure.

    Conclusions:

    • Ranolazine shows potential as an effective treatment for stable angina and intermittent claudication.
    • Its unique mechanism of action may benefit patients refractory to conventional therapies.
    • Further clinical evaluation is ongoing to confirm its therapeutic role.